Universal Corporation — Form 10-Q Summary
Period: The filing is for the quarter ended December 31, 2022 (Universal’s fiscal 2023 third quarter), and the nine months then ended. This differs from the request metadata, which says 2021 Q3. Dollar amounts below are in millions unless noted.
Business context
Universal is a global business-to-business supplier, principally of leaf tobacco, with a growing plant-based ingredients business serving food and beverage markets. The company says its operations are seasonal, so interim results may not indicate full-year performance.
Financial results and liquidity
| Metric | Quarter ended Dec. 31, 2022 | Quarter ended Dec. 31, 2021 | Nine months ended Dec. 31, 2022 | Nine months ended Dec. 31, 2021 |
|---|---|---|---|---|
| Revenue | $795.0 | $652.6 | $1,875.8 | $1,456.6 |
| Operating income | $77.5 | $62.8 | $128.7 | $103.2 |
| Net income attributable to Universal | $41.7 | $34.9 | $70.3 | $60.8 |
| Diluted EPS | $1.67 | $1.40 | $2.82 | $2.44 |
| Gross profit margin | 18.3%* | 20.1%* | 17.9% | 19.7% |
*Calculated from reported revenue and cost of goods sold. For the nine-month period, revenue rose 29%, while gross margin contracted 180 basis points. Management attributed margin pressure primarily to sales mix and lower-margin tobacco sales, including tobacco written down in prior quarters.
- Cash flow: Operating activities used $183.9 million in the nine months, versus $51.6 million used in the prior-year period. Management cited higher seasonal working-capital needs, especially increased green tobacco costs and shipment timing. Capital expenditures were $39.4 million; investing cash outflow was $34.6 million.
- Balance sheet at Dec. 31, 2022: Cash was $71.3 million; short-term notes payable and overdrafts were $348.1 million; long-term debt was $616.8 million. Net debt to net capitalization was approximately 40%, compared with 35% a year earlier and 32% at March 31, 2022.
- Liquidity: The company reported $330 million available on its committed revolving facility and approximately $196 million in uncommitted credit lines. It said available resources exceeded normal working-capital needs and anticipated capital expenditures for the next 12 months. It was in compliance with debt covenants.
- Dividends and repurchases: Dividends declared were $0.79 per share for the quarter and $2.37 for the nine months. No shares were repurchased during the quarter; the new repurchase authorization allows up to $100 million through November 15, 2024.
Changes and operating performance
- Quarterly revenue increased $142.4 million year over year, primarily on higher tobacco sales volumes and prices. Nine-month revenue increased $419.2 million, reflecting tobacco growth and the addition of Shank’s Extracts, acquired in October 2021.
- Tobacco Operations revenue increased 29% for the nine months, to $1,642.7 million, and operating income rose 13%, to $119.0 million. Higher shipments supported results, but margins were lower due to sales mix and lower-margin tobacco sales. Management reported undersupplied leaf markets and uncommitted inventory below 7% of tobacco inventory.
- Ingredients Operations nine-month revenue increased 24%, to $233.2 million, while operating income declined 7%, to $9.9 million. In the quarter, segment revenue fell to $70.5 million from $74.6 million and operating income fell to $0.8 million from $3.5 million. Management cited softer demand for some products, customer inventory adjustments, higher costs, and lower extract sales in the quarter.
- Interest expense increased to $14.3 million for the quarter and $33.3 million for the nine months, largely reflecting higher debt balances and rates. The company refinanced its bank facility in December 2022, extending maturities and establishing a $530 million revolver and funded term loans of $275 million and $345 million. Swaps fixed rates on half of each term loan; the reported effective rates on those hedged portions were 5.50% and 5.65%.
- No restructuring or impairment costs were recorded in the 2022 periods; the prior-year comparisons included restructuring and impairment charges. Reported nine-month diluted EPS was $2.82 versus $2.44; adjusted diluted EPS, a non-GAAP measure, was $2.80 versus $2.76.
Outlook, commentary, risks and contingencies
- Management said tobacco shipments were moving more smoothly than in the prior fiscal year and expected seasonal working-capital needs to contract after the peak. It described larger crops in several key tobacco origins in fiscal 2024 as a forecast, while noting it was early.
- Management expects to spend approximately $70–$80 million on capital projects over the next 12 months, including investments in the plant-based ingredients platform. No earnings or revenue guidance is provided in the filing.
- Management sees temporary softness in demand for some ingredients products, which it attributes largely to customers adjusting inventories. It remains positive about the platform’s longer-term prospects and reports progress on operational synergies.
- Risks identified include customer concentration, tobacco supply and crop conditions, shipment timing and logistics, inflation and input costs, foreign-exchange and interest-rate changes, geopolitical and economic conditions including the conflict in Ukraine, regulation, and acquisition integration. Management said COVID-19 was not then expected to materially affect financial condition, results, or demand, while continuing to monitor related shipping constraints and costs.
- Brazil VAT assessments remain contested: approximately $9 million in Santa Catarina and $3 million in Paraná, including accumulated interest as applicable. Management and counsel consider no loss probable; no liability was recorded. The company also reported approximately $66 million of gross recoverable VAT credits with $24 million in valuation allowances, and $186 million of supplier advances with $21 million in allowances.
- The sale of the idled Tanzania operations was for $8.5 million; $3.2 million had been received by December 31, 2022, with remaining installments expected by June 2023. The sale generated $1.1 million of income taxes and reduced interest expense by $1.8 million through removal of an uncertain tax position.
Important facts for investors to verify
- Confirm the intended reporting period: this filing covers fiscal Q3 2023, not 2021 Q3.
- Track working-capital and operating cash-flow trends, especially tobacco inventory, receivables, and short-term borrowing as seasonal needs unwind.
- Assess whether tobacco shipment volumes and pricing can sustain operating income despite lower margins and undersupplied crops.
- Monitor Ingredients Operations demand, margins, and expense growth, including returns on platform investments and acquisition-related costs.
- Review debt costs, variable-rate exposure, covenant headroom, and the availability of committed and uncommitted credit.
- Follow outcomes of the Brazil VAT disputes, recoverability of VAT credits and supplier advances, and collection of the remaining Tanzania sale proceeds.